DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)--Neos Therapeutics, Inc. (NASDAQ: NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (“XR”) product candidates for ...
Dec 20 (Reuters) - Drug developer Neos Therapeutics Inc said on Tuesday it resubmitted the marketing application for its attention deficit/hyperactivity disorder (ADHD) drug to the U.S. Food and Drug ...
Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) - Neos Therapeutics Inc said the U.S. Food and Drug Administration identified deficiencies that preclude discussion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results